Startseite>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>(S)-Naproxen

(S)-Naproxen (Synonyms: CG 3117, (S)-Naproxen)

Katalog-Nr.GC14820

(S)-Naproxen ist ein COX-1- und COX-2-Inhibitor mit IC50-Werten von 8,72 bzw. 5,15 &7#956;M im Zellassay.

Products are for research use only. Not for human use. We do not sell to patients.

(S)-Naproxen Chemische Struktur

Cas No.: 22204-53-1

Größe Preis Lagerbestand Menge
25g
74,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment:

BAEC are incubated for 30 min with Naproxen (0.1 ng/mL to 1 mg/mL). Arachidonic acid (30 μM) is then added, and the cells are incubated for a further 15 min at 37°C. The medium is then removed, and radioimmunoassay is used to measure the formation of 6-keto-PGF,a, PGE2, thromboxane B2, or PGF2a[1].

Animal experiment:

Rats[3]To measure the analgesic effects of naproxen in a carrageenaninduced model of monoarthritis, Male Sprague–Dawley rats (n=48, 217±28 g) are randomly divided into four groups of 12 by an internally developed computer program, allowing the blind performance of the behavioral experiment. To induce hyperalgesia by inflammation, animals in groups 1B, 1C, and 1D receive a 40-μL intra-articular injection of a saline solution containing 7.5 mg/mL carrageenan in the left hind limb under isoflurane anesthesia (time=−1 h). Animals in group 1A receive no injection. After 1 h (time=0) the animals in groups 1A, 1B, 1C, and 1D receive oral doses of naproxen in saline of 0, 0, 7.5 and 30 μmol/kg, respectively. The doses and time points of measurements are selected on the basis of simulations predicting measuring a full concentration-effect relationship within the time-span of the experiment[3].Mice[2]Bleomycin (0.05 IU) is instilled intratracheally to C57BL/6 mice, which are then treated by micro-osmotic pump with vehicle, JNJ7777120 (40 mg/kg b.wt.), naproxen (21 mg/kg b.wt.), or a combination of both. Airway resistance to inflation, an index of lung stiffness, is assessed, and lung specimens are processed for inflammation, oxidative stress, and fibrosis markers[2].

References:

[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7.
[2]. Rosa AC, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther. 2014 Nov;351(2):308-16.
[3]. Krekels EH, et al. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats.

Background

(S)-Naproxen is a non-selective COX inhibitor [1,2].

Cyclooxygenase (COX) is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Cyclooxygenase enzymes have been involved in diverse physiological situations and disease processes ranging from inflammation to cancer. Until now, two cyclooxygenase isoforms have been identified, COX-1 and COX-2. The COX-1 enzyme is produced constitutively (i.e., gastric mucosa) and COX-2 is inducible (i.e., sites of inflammation) [3].

(S)-Naproxen inhibited the activity of human recombinant COX-1 and -2 with the IC50 values of 0.6-4.8 μM and 2.0-28.4 μM, respectively [1]. (S)-naproxen bound tightly to Aβfibrils with the Ki value of 5.70 ± 1.31 nM against [18F]FDDNP [2]. Pretreatment with (S)-naproxen significantly reduced the specific binding of [18F]FDDNP to regions of gray matter with SPs in AD specimens [4].

References:
[1] Barnett J, Chow J, Ives D, et al.  Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system[J]. Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology, 1994, 1209(1): 130-139.
[2] Laneuville O, Breuer D K, Dewitt D L, et al.  Differential inhibition of human prostaglandin endoperoxide H synthases-1 and-2 by nonsteroidal anti-inflammatory drugs[J]. Journal of Pharmacology and Experimental Therapeutics, 1994, 271(2): 927-934.
[3] Dubois R N, Abramson S B, Crofford L, et al.  Cyclooxygenase in biology and disease[J]. The FASEB journal, 1998, 12(12): 1063-1073.
[4] Agdeppa E D, Kepe V, Petri A, et al.  In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18 F] fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene) malononitrile[J]. Neuroscience, 2003, 117(3): 723-730.

Chemical Properties

Cas No. 22204-53-1 SDF
Überlieferungen CG 3117, (S)-Naproxen
Chemical Name (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid
Canonical SMILES C[C@H](C(O)=O)C1=CC=C2C=C(OC)C=CC2=C1
Formula C14H14O3 M.Wt 230.3
Löslichkeit DMF: >25 mg/ml,DMSO: >24 mg/ml,Ethanol: >55 mg/ml,PBS pH 7.2: 1 mg/ml Storage Room temperature
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 4.3422 mL 21.7108 mL 43.4216 mL
5 mM 0.8684 mL 4.3422 mL 8.6843 mL
10 mM 0.4342 mL 2.1711 mL 4.3422 mL
  • Molaritätsrechner

  • Verdünnung-Rechner

Gewicht
=
Konzentration
x
Inhalt
x
MW*
 
 
 
**Bei der Herstellung von Stammlösungen ist immer das chargenspezifische Molekulargewicht von

Berechnen

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Bewertungen

Review for (S)-Naproxen

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (S)-Naproxen

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.